KUNMING LONGJIN PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.67 CNY | -4.92% |
|
-19.34% | -63.30% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 2,243 | 5,154 | 3,356 | 6,460 | 4,458 | 4,005 |
| Enterprise Value (EV) 1 | 1,849 | 4,751 | 2,945 | 6,032 | 4,054 | 3,672 |
| P/E ratio | 162 x | -223 x | 284 x | 2,095 x | -79.4 x | -56.5 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 6.68 x | 18.7 x | 13.2 x | 9.2 x | 36.3 x | 46.2 x |
| EV / Revenue | 5.5 x | 17.3 x | 11.6 x | 8.59 x | 33 x | 42.4 x |
| EV / EBITDA | 97.7 x | 387 x | 156 x | 440 x | -159 x | -117 x |
| EV / FCF | -940 x | 164 x | -77.9 x | 160 x | -141 x | -83.1 x |
| FCF Yield | -0.11% | 0.61% | -1.28% | 0.63% | -0.71% | -1.2% |
| Price to Book | 3.46 x | 8.26 x | 5.28 x | 10.1 x | 7.65 x | 7.82 x |
| Nbr of stocks (in thousands) | 400,500 | 400,500 | 400,500 | 400,500 | 400,500 | 400,500 |
| Reference price 2 | 5.600 | 12.87 | 8.380 | 16.13 | 11.13 | 10.00 |
| Announcement Date | 19-03-12 | 20-04-28 | 21-04-14 | 22-04-29 | 23-04-20 | 24-04-29 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 336 | 275.3 | 254 | 702.5 | 123 | 86.62 |
| EBITDA 1 | 18.91 | 12.26 | 18.82 | 13.72 | -25.42 | -31.38 |
| EBIT 1 | -3.859 | -13.91 | -9.432 | -16.88 | -55 | -61.79 |
| Operating Margin | -1.15% | -5.05% | -3.71% | -2.4% | -44.73% | -71.33% |
| Earnings before Tax (EBT) 1 | 15.68 | -22.39 | 7.313 | -5.564 | -68.73 | -82.24 |
| Net income 1 | 13.87 | -23.11 | 11.81 | 3.093 | -56.12 | -70.94 |
| Net margin | 4.13% | -8.39% | 4.65% | 0.44% | -45.64% | -81.9% |
| EPS 2 | 0.0346 | -0.0577 | 0.0295 | 0.007700 | -0.1401 | -0.1771 |
| Free Cash Flow 1 | -1.967 | 29.03 | -37.78 | 37.75 | -28.73 | -44.2 |
| FCF margin | -0.59% | 10.54% | -14.87% | 5.37% | -23.37% | -51.03% |
| FCF Conversion (EBITDA) | - | 236.68% | - | 275.07% | - | - |
| FCF Conversion (Net income) | - | - | - | 1,220.36% | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 19-03-12 | 20-04-28 | 21-04-14 | 22-04-29 | 23-04-20 | 24-04-29 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 394 | 404 | 412 | 428 | 403 | 333 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -1.97 | 29 | -37.8 | 37.8 | -28.7 | -44.2 |
| ROE (net income / shareholders' equity) | 2.12% | -3.62% | 1.13% | -1.08% | -11.5% | -14.7% |
| ROA (Net income/ Total Assets) | -0.31% | -1.09% | -0.72% | -1.26% | -4.37% | -5.6% |
| Assets 1 | -4,524 | 2,119 | -1,652 | -244.7 | 1,285 | 1,267 |
| Book Value Per Share 2 | 1.620 | 1.560 | 1.590 | 1.600 | 1.460 | 1.280 |
| Cash Flow per Share 2 | 0.9600 | 0.4900 | 0.3100 | 0.2500 | 0.4800 | 0.5300 |
| Capex 1 | 15.5 | 7.07 | 23.6 | 10.4 | 25.2 | 15.7 |
| Capex / Sales | 4.62% | 2.57% | 9.29% | 1.47% | 20.51% | 18.08% |
| Announcement Date | 19-03-12 | 20-04-28 | 21-04-14 | 22-04-29 | 23-04-20 | 24-04-29 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -63.30% | 204M | |
| +21.63% | 44.11B | |
| +23.03% | 22.71B | |
| +18.22% | 15.15B | |
| +12.66% | 13.56B | |
| +60.18% | 12.7B | |
| -10.02% | 6.84B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +12.92% | 5.63B |
- Stock Market
- Equities
- 002750 Stock
- Financials Kunming Longjin Pharmaceutical Co., Ltd.